Syndax Pharmaceuticals Financials
| 1T3 Stock | EUR 12.80 0.10 0.78% |
Syndax |
Understanding current and past Syndax Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Syndax Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Syndax Pharmaceuticals' assets may result in an increase in income on the income statement.
Syndax Pharmaceuticals Stock Summary
Syndax Pharmaceuticals competes with KOOL2PLAY, TRAVEL LEISURE, PLAYTIKA HOLDING, Carsales, and InPlay Oil. Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company was founded in 2005 and is headquartered in Waltham, Massachusetts. Syndax Pharmaceuticals operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 38 people.| Instrument | Germany Stock View All |
| Exchange | Frankfurt Exchange |
| ISIN | US87164F1057 |
| Business Address | 35 Gatehouse Drive, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.syndax.com |
| Phone | 781 419 1400 |
| Currency | EUR - Euro |
You should never invest in Syndax Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Syndax Stock, because this is throwing your money away. Analyzing the key information contained in Syndax Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Syndax Pharmaceuticals Key Financial Ratios
There are many critical financial ratios that Syndax Pharmaceuticals' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Syndax Pharmaceuticals reports annually and quarterly.| Return On Equity | -0.0519 | |||
| Return On Asset | -0.0292 | |||
| Target Price | 27.67 | |||
| Number Of Employees | 59 | |||
| Beta | 1.06 |
Syndax Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Syndax Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Syndax Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Syndax Pharmaceuticals competition to find correlations between indicators driving Syndax Pharmaceuticals's intrinsic value. More Info.Syndax Pharmaceuticals is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Syndax Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Syndax Pharmaceuticals Systematic Risk
Syndax Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Syndax Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Syndax Pharmaceuticals correlated with the market. If Beta is less than 0 Syndax Pharmaceuticals generally moves in the opposite direction as compared to the market. If Syndax Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Syndax Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Syndax Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Syndax Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Syndax Pharmaceuticals December 18, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Syndax Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Syndax Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Syndax Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Syndax Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Syndax Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 32.68 | |||
| Value At Risk | (5.04) | |||
| Potential Upside | 6.47 |
Complementary Tools for Syndax Stock analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |